IP Library Granted Patent US 8,591,862
Granted Patent B2
US 8,591,862 · App. 13/184,068 · Granted Nov 26, 2013

Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells

Inventors: Himanshu Brahmbhatt (Sydney, AU); Jennifer Macdiarmid (Sydney, AU)
Assignee: Engeneic Molecular Delivery Pty Ltd
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,591,862
App. No.
13/184,068
Granted
Nov 26, 2013
Kind
B2
Abstract

A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.

Claims (16)

1. A delivery method that comprises bringing a composition comprising (a) a plurality of intact killed S. typhimurium cells that contain an agent selected from the group consisting of a functional nucleic acid, a therapeutic nucleic acid and a drug and (b) a ligand that carries specificity for a non-phagocytic mammalian cell surface receptor that activates receptor-mediated endocytosis into contact with endocytosis-competent mammalian cells, such that said intact killed S. typhimurium cells are endocytosed by said mammalian cells via receptor-mediated endocytosis, thereby delivering said agent to said mammalian cells.

2. The method of claim 1 , wherein said plurality contains a therapeutically significant concentration of said agent.

3. The method of claim 1 , wherein said contact is in vivo.

4. The method of claim 1 , wherein said contact is in vitro.

5. The method of claim 1 , wherein said agent is a functional nucleic acid.

6. The method of claim 5 , wherein said plurality contains a therapeutically significant concentration of said functional nucleic acid and there is an absence from said intact killed bacterial cells of a construct for in situ expression of said functional nucleic acid.

7. The method of claim 5 , wherein said composition further comprises a drug.

8. The method of claim 7 , wherein said functional nucleic acid targets the transcript of a protein that contributes to resistance to said drug.

9. The method of claim 8 , wherein said drug is packaged in the killed bacterial cell.

10. The method of claim 1 , wherein said agent is a therapeutic nucleic acid.

11. The method of claim 10 , wherein said therapeutic nucleic acid is encoded by a plasmid.

12. The method of claim 11 , wherein said plasmid is released from said intact killed S. typhimurium cells into said mammalian cells and expressed in said mammalian cells.

13. The method of claim 10 , wherein said therapeutic nucleic acid encodes a suicide gene.

14. The method of claim 1 , wherein said agent is a drug.

15. The method of claim 14 , wherein said drug is a small molecule drug.

16. The method of claim 14 , wherein said drug is a cancer chemotherapeutic agent.

Assignments (1)
CHANGE OF NAME Recorded Oct 21, 2013
From: ENGENEIC GENE THERAPY PTY LIMITED
To: ENGENEIC MOLECULAR DELIVERY PTY LTD
Reel/Frame 031447/0573 →
Continuity (4)
Division 11765635 · Jun 20, 2007
Provisional Application 60815883 · Jun 23, 2006
Provisional Application 60909078 · Mar 30, 2007
Related Publication 20110275585A1 · Nov 10, 2011